摘要
目的比较XELOX与FOLFOX两种新辅助化疗方案治疗进展期直肠癌的临床疗效、安全性和生存率。方法收集我院71名进展期直肠癌患者作为研究对象,随机分为观察组(35例)和对照组(36例),观察组术前予XELOX方案行新辅助化疗,对照组术前予FOLFOX方案行新辅助化疗,两组患者化疗后接受腹腔镜直肠癌根治手术,术后进行辅助化疗,比较两组患者的化疗疗效、不良反应以及手术风险和术后生存率。结果两组患者的化疗疗效、手术时间、术中出血量、术后引流管拔除时间、肛门排气时间、住院时间、无瘤生存率及总生存率的差异均无统计学意义(P>0.05)。在化疗毒副反应方面,观察组白细胞下降的发生率(31.42%)明显低于对照组(55.55%);而观察组手足综合征的发生率(48.57%)高于对照组(0%),差异均有统计学意义(P<0.05)。结论 XELOX方案使用方便,疗效与FOLFOX方案相当,是一种可以接受的替代治疗选择。
Objective To compare the clinical effects, toxicities and survival rate between XELOX and FOLFOX regi- mens as neoadjuvant chemotherapy for patients with advanced retal carcinoma. Methods A total of 71 patients with ad- vanced retal carcinoma in our hospital were selected and randomly divided into observation group （35 cases） and control group （36 cases）. The observation group was treated with XELOX regimen before operation while the control group with FOLFOX regimen. All the patients received laparoscopic total mesorectal excision after neoadjuvant chemotherapy. Patients went on the same way of chemotherapy in each group after operation. The clinical effects, toxicity, surgical data, survival rate of the two groups were collected and analyzed. Results There was no statistic difference in clinical effects, surgical time, in- traoperative blood loss, time for removing drainage tube, time for anal exhaust, hospitalization time, tumor-free survival rate and overall survival rate between the two groups. The rate of leukocyte decrease was significantly lower in observation group （31.42%） than in control group （55.55%）, while the rate of hand-foot syndrome was significantly higher in observation group （48.57%） than in the control group （0%）. Conclusion XELOX regimen is as effective as FOLFOX regimen. It is an accept- able alternative ontion of neoadjuvant chemotherapy.
出处
《肿瘤药学》
CAS
2016年第1期70-73,共4页
Anti-Tumor Pharmacy
关键词
直肠癌
新辅助化疗
XELOX
Rectal carcinoma
Neoadjuvant chemotherapy
XELOX
作者简介
何盛泉，男，硕士、主治医师，研究方向：普通外科，E—mail：egghsq@21cn．com。
